AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BridgeBio Pharma, Inc. Director's Dealing 2023

Apr 7, 2023

30604_dirs_2023-04-07_9ab286bb-d714-4749-83ca-a4b75195830c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2023-04-05

Reporting Person: STEPHENSON BRIAN C (Secretary, Treasurer & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-05	Common Stock	S	55500	$15.454	Disposed	101337	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 6, 2022.

F2: Represents the weighted average sale price of the shares sold from $15.20 to $15.78 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.